Cardiotoxicidade associada aos inibidores de checkpoint: relato de caso: Cardiotoxicity associated with checkpoint inhibitors: report case

Introdução: A evolução da imunoterapia no manejo do paciente oncológico tem se constituído em importante arsenal terapêutico das neoplasias malignas. Entretanto, deve-se conhecer os mecanismos de ação e os principais efeitos colaterais das drogas para adequada monitorização durante o tratamento. Objetivo- Relatar a ocorrência de miocardite após uso de imunoterapia para tratamento de adenocarcinoma de pulmão. Método–Trata-se de um caso clínico, cujas informações foram obtidas mediante análise cuidadosa do prontuário médico, da anamnese e da avaliação dos laudos dos exames complementares submetidos pelo paciente e de revisão de literatura. Conclusão Foi abordado um dos efeitos colaterais mais graves ocasionados por inibidores de checkpoint: a toxidade cardíaca.  O diagnóstico precoce permitiu a interrupção da imunoterapia e evitou eventos adversos maiores

Multifactorial Etiology Pulmonary Hypertension in a Patient with Sarcoidosis

Differential diagnosis between pre- and postcapillary pulmonary hypertension (PH) in patients with diastolic heart failure (DHF) is a challenge in clinical practice. The presence of PH is implicated in worse prognosis in patients with this disease. This case report approaches the process of investigation of pulmonary hypertension in adult patient with DHF, double mitral lesion, and sarcoidosis with poor clinical outcome

Moving towards establishing centres of excellence in cardiac amyloidosis: an International Cardio-Oncology Society statement

The prevalence of amyloidosis has been increasing, driven by a combination of improved awareness, evolution of diagnostic pathways, and effective treatment options for both transthyretin and light chain amyloidosis. Due to the complexity of amyloidosis, centralised expert providers with experience in delineating the nuances of confirmatory diagnosis and management may be beneficial. There are many potential benefits of a centre of excellence designation for the treatment of amyloidosis including recognition of institutions that have been leading the way for the optimal treatment of this condition, establishing the expectations for any centre who is engaging in the treatment of amyloidosis and developing cooperative groups to allow more effective research in this disease space. Standardising the expectations and criteria for these centres is essential for ensuring the highest quality of clinical care and community education. In order to define what components are necessary for an effective centre of excellence for the treatment of amyloidosis, we prepared a survey in cooperation with a multidisciplinary panel of amyloidosis experts representing an international consortium. The purpose of this position statement is to identify the essential elements necessary for highly effective clinical care and to develop a general standard with which practices or institutions could be recognised as a centre of excellence

Multifactorial Etiology Pulmonary Hypertension in a Patient with Sarcoidosis

Differential diagnosis between pre- and postcapillary pulmonary hypertension (PH) in patients with diastolic heart failure (DHF) is a challenge in clinical practice. The presence of PH is implicated in worse prognosis in patients with this disease. This case report approaches the process of investigation of pulmonary hypertension in adult patient with DHF, double mitral lesion, and sarcoidosis with poor clinical outcome